An interventional study of Virtual Reality Headset in Pregnancy Related, Pain and Anxiety, sponsored by Serpil Uyar. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Serpil Uyar · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,720 studies in Pain with a site in Turkey — 323 open to participants now, 376 under way, none of them phase 3. Pain · Turkey.
Among the 1,720 studies in Pain with a site in Turkey, this one is the 31st largest by planned enrollment of the 1,497 interventional ones that give a count, is one of 283 that started in 2025, is one of 1,455 with no phase, reaches primary completion later than 289 of the 375 other live ones, and was the 1,717th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →323 of the 1,720 studies in Pain with a site in Turkey are open now. Recruiting first, the newest first:
Mersin University · Sites in Turkey
Ages 18+
Artvin Coruh University · Sites in Turkey
Ages 6–12
Mersin University · Sites in Turkey
Ages 18+
Bahçeşehir University · Sites in Turkey
Ages 45–65
Istanbul University · Sites in Turkey
Ages 1–12
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 19 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,720 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6 · Phase 4 34
First in 2006; this study’s year is marked. 283 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 70 across the 1,497 interventional studies, 84 across the 223 observational. Of the 1,272 that completed or were terminated, 7 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 1,720 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Serpil Uyar as lead sponsor.
Serpil Uyar has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
88 of the studies in Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846098Cumhuriyet UniversityComparison of Intraosseous Anesthesia and Inferior Alveolar Nerve Block for Primary Mandibular Molars | 2026-11-20 |
| NCT07404163Tarsus UniversityWalkway Used in Postoperative Mobilization | 2026-11-30 |
| NCT07915804Istanbul UniversityPerfusion Index for Postoperative Pain Assessment in Pediatric Adenotonsillectomy | 2026-11-30 |
| NCT07892196Antalya Training and Research HospitalDoes Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy? | 2026-11-30 |
| NCT07936604Harran UniversityMotor Control Exercise and Myofascial Release in Greater Trochanteric Pain Syndrome | 2026-11-30 |
Add all 88 to your calendar (.ics) → With an account.
Among the 1,720 studies in Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Our study aims to investigate the impact of virtual reality headset use on pain, anxiety, and vital signs in pregnant women after they receive a vaccine. Pain and anxiety will be assessed using relevant scales, while vital signs-specifically blood pressure, pulse, and oxygen saturation-will be measured using a blood pressure monitor and a pulse oximeter.
The study is conducted at the Afyonkarahisar Family Health Centre No. 6-the facility where the researcher is employed-between December 1, 2025, and December 1, 2026. This location was selected to facilitate access to the target group, ensure an efficient and reliable data collection process, and enhance the overall feasibility of the research.
The study population will consist of pregnant women who visit the Family Health Centre for pregnancy follow-ups or vaccinations during the specified study period. The research will involve two groups: one control group (Group 1) and one intervention group (Group 2).
Given the interventional nature of this study-and noting that no existing literature could be found examining the effects of virtual reality (VR) headsets on anxiety, pain, or vital signs in pregnant women undergoing vaccination-a pilot study involving at least 30 participants will be conducted first. Subsequently, a power analysis will be performed using the G*Power 3.1 software to determine the final sample size. The projected sample size is 100 participants for Group 1 and 100 for Group 2, totalling 200 participants.
Assignment to the intervention and control groups will take place when pregnant women who meet the inclusion criteria arrive at Family Health Centre No. 06. A sealed-envelope method will be used to ensure randomisation when allocating the pregnant women into the intervention and control groups. Envelopes will contain slips of paper marked with either an odd or an even number. Those who select an odd number will be assigned to the control group (Group 1), while those who select an even number will be assigned to the intervention group (Group 2).
A single-blind approach will be employed, in which the individuals responsible for entering data into the SPSS software and those conducting the statistical analyses will be blinded. Data entry will be performed by individuals who have no knowledge of the study groups, and statistical analyses will be conducted by a statistician who is also unaware of the study groups.
Data for the study will be collected using a sociodemographic characteristics form, a pre-vaccination pregnancy monitoring form, and a post-vaccination pregnancy monitoring form.
All pregnant women arriving for vaccination who meet the inclusion criteria will be provided with information about the study, after which they will complete a sociodemographic characteristics form. Subsequently, participants will be randomised into groups using an envelope method.
Group 1 (Control Group) will not watch a pre-vaccination video via virtual reality (VR) headsets; however, data will be collected using a pre-vaccination monitoring form (before the vaccination) and a post-vaccination monitoring form (after the vaccination).
Group 2 (Experimental Group) will first complete the pre-vaccination monitoring form, followed by a 5-minute video session using VR headsets. The vaccination will be administered after the video, and data will be collected 5 minutes post-vaccination using the post-vaccination monitoring form.
Since the virtual reality intervention in our study is specific to the pre-vaccination period, applying it to the control group at a later stage would not be methodologically appropriate.
In this study, the administration of the virtual reality intervention, the recording of vital signs, and the completion of the forms will be carried out by the researcher.
Pregnancy and childbirth constitute a natural process in a woman's life, characterised by physiological, psychological, and social changes driven by hormonal shifts, physical transformations, and environmental factors. This process holds different meanings for every woman; while for some it is a source of happiness, for others, it may be a period marked by uncertainty and the unknown. Receiving a tetanus vaccine during pregnancy is critically important for protecting infants against fatal neonatal tetanus. It is recommended that all pregnant women receive one dose of the Tdap vaccine during their pregnancy. In addition to protecting the mother, the Tdap vaccine protects the infant after birth-until the baby's own vaccinations are administered-through the transfer of maternal antibodies from mother to child. Therefore, a tetanus vaccine should be administered to all pregnant women who were not vaccinated during childhood, whose vaccination status is unknown, who are incompletely vaccinated, or who are fully vaccinated but have not received a booster dose within the last 10 years. For pregnant women who have never been vaccinated, it is recommended that they receive two doses of a tetanus-containing vaccine, spaced 4 weeks apart, with at least one of these being the Tdap (tetanus, diphtheria, and acellular pertussis) vaccine. Pregnant women who receive a dose of the Tdap vaccine between 18 and 24 weeks of gestation should receive a dose of the Td (tetanus-diphtheria) vaccine 4 weeks later. Since the protective effect of the vaccine reaches an adequate level one month after the second dose, this vaccination schedule should be completed at least one month before childbirth. Due to the uncertainties surrounding pregnancy, some pregnant women experience anxiety. Numerous studies have indicated that anxiety during pregnancy may be associated with sociodemographic factors, such as the woman's age, marital status, number of children, educational level, use of tobacco, alcohol, or other substances, and whether the pregnancy was planned. Pain during pregnancy can arise from physiological changes-such as an increase in blood volume, shifts in fluid-electrolyte balance, and hormonal fluctuations-as well as anatomical changes, including adaptations to the growing fetus, a shift in the center of gravity, and the softening of pelvic joints. Virtual reality (VR) immerses individuals by replacing or augmenting sensory input with computer-generated data, creating the perception that the user is in a different environment; it is increasingly used in healthcare. Virtual reality is an effective method for reducing anxiety. As a relaxation technique, virtual reality helps suppress adrenaline while promoting the release of endorphins and oxytocin. Furthermore, by diverting attention and leveraging these hormonal effects, it helps regulate mood and emotional state, thereby contributing to a reduction in anxiety. A review of the literature indicates that the use of virtual reality headsets during medical procedures can decrease anxiety in pregnant women, reduce the perception of pain through distraction, and enhance satisfaction both during and after the procedure. Additionally, the use of virtual reality headsets among pregnant women has been found to have positive effects on the physiological parameters of the fetus. However, no study has been found that examines the effect of using virtual reality headsets on pain, anxiety, and vital signs in pregnant women following vaccination. Our study aims to investigate the impact of virtual reality headset use on pain, anxiety, and vital signs in pregnant women after they receive a vaccine. Pain and anxiety will be assessed using relevant scales, while vital signs-specifically blood pressure, pulse, and oxygen saturation-will be measured using a blood pressure monitor and a pulse oximeter.
The study is conducted at the Afyonkarahisar Family Health Centre No. 06-the facility where the researcher is employed-between December 1, 2025, and December 1, 2026. This location was selected to facilitate access to the target group, ensure an efficient and reliable data collection process, and enhance the overall feasibility of the research.
The study population will consist of pregnant women who visit the Family Health Centre for pregnancy follow-ups or vaccinations during the specified study period. The research will involve two groups: one control group (Group 1) and one intervention group (Group 2).
Given the interventional nature of this study-and noting that no existing literature could be found examining the effects of virtual reality (VR) headsets on anxiety, pain, or vital signs in pregnant women undergoing vaccination-a pilot study involving at least 30 participants will be conducted first. Subsequently, a power analysis will be performed using the G*Power 3.1 software to determine the final sample size. The projected sample size is 100 participants for Group 1 and 100 for Group 2, totalling 200 participants.
Assignment to the intervention and control groups will take place when pregnant women who meet the inclusion criteria arrive at Family Health Centre No. 06. A sealed-envelope method will be used to ensure randomisation when allocating the pregnant women into the intervention and control groups. Envelopes will contain slips of paper marked with either an odd or an even number. Those who select an odd number will be assigned to the control group (Group 1), while those who select an even number will be assigned to the intervention group (Group 2).
A single-blind approach will be employed, in which the individuals responsible for entering data into the SPSS software and those conducting the statistical analyses will be blinded. Data entry will be performed by individuals who have no knowledge of the study groups, and statistical analyses will be conducted by a statistician who is also unaware of the study groups.
Data for the study will be collected using a sociodemographic characteristics form, a pre-vaccination pregnancy monitoring form, and a post-vaccination pregnancy monitoring form.
All pregnant women arriving for vaccination who meet the inclusion criteria will be provided with information about the study, after which they will complete a sociodemographic characteristics form. Subsequently, participants will be randomised into groups using an envelope method.
Group 1 (Control Group) will not watch a pre-vaccination video via virtual reality (VR) headsets; however, data will be collected using a pre-vaccination monitoring form (before the vaccination) and a post-vaccination monitoring form (after the vaccination).
Group 2 (Experimental Group) will first complete the pre-vaccination monitoring form, followed by a 5-minute video session using VR headsets. The vaccination will be administered after the video, and data will be collected 5 minutes post-vaccination using the post-vaccination monitoring form.
Since the virtual reality intervention in our study is specific to the pre-vaccination period, applying it to the control group at a later stage would not be methodologically appropriate.
In this study, the administration of the virtual reality intervention, the recording of vital signs, and the completion of the forms will be carried out by the researcher.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Virtual Reality Headset Intervention Group participants will watch a 5-minute video via Virtual Reality Headsets before the vaccination in addition to the standard care throughout the procedure.
Device: Virtual Reality Headset
The Control Group participants will receive only the standard care throughout the procedure.
A 5-minute video, which includes relaxing, calming, motivating and fear-free nature scenes, cover gently wavy sea, calm beach, hotel pool, snowy mountains, sky, waterfalls, lake and forest, will be presented to the participants via Virtual Reality Headsets before the vaccination.
Visual Analog Scale for Pain (VAS)
VAS scale is a single-dimensional scale that is commonly used to evaluate pain severity. According to VAS, pain intensity is rated as "no pain" with 0 points, and "the most severe pain imaginable" with 10 points. Pain intensity ranges were determined by VAS as follows; mild pain below 3 points, as moderate pain between 3 and 6 points, and as severe pain above 6 points.The VAS pain scale will be applied to the participants before the 5 minutes before the procedure and 5 minutes after the procedure.
Time frame: 15 minutes
State-Trait Anxiety Inventory (STAI-S)
The State-Trait Anxiety Inventory (STAI) consists of two subscales: the State-Trait Anxiety Inventory (STAI-S) measures the anxiety an individual feels at a specific moment, while the Trait Anxiety Inventory (STAI-T) assesses the individual's general anxiety tendency. Each subscale consists of 20 items and is scored using a 4-point Likert scale; some items are reverse-scored. Subscale scores range from 20 to 80, with higher scores indicating higher anxiety. In this study, only the 20-item State-Trait Anxiety Inventory (STAI-S) subscale of the STAI was used to measure the immediate anxiety level. State-Trait Anxiety Inventory (STAI-S) will be applied to the participants before the 5 minutes before the procedure and 5 minutes after the procedure.
Time frame: 15 minutes
Vital Signs
The systolic and diastolic blood pressure will be measured with An Omron RS1 wrist blood pressure monitor by the researchers.
Time frame: 15 minutes
Vital Signs
Heart rate values of the participants will be measured with a An Endostall pulse oximeter by the researchers.
Time frame: 15 minutes
Vital Signs
SpO2 values of the participants will be measured with a An Endostall pulse oximeter by the researchers.
Time frame: 15 minutes
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 12 months is above that.
Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.